{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:40:57Z","timestamp":1791592857198,"version":"4.3.4"},"reference-count":62,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:p>Background: The NIA-AA Research Framework on Alzheimer\u2019s disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS). Objective: To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals. Methods: We included baseline data of N\u200a=\u200a338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on A\u03b242\/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed. Results: We identified three distinct participant clusters based on presented symptoms. The highest rate of A+\u200aparticipants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower A\u03b242\/ptau181 ratio compared to those with neither SCD nor OBJ. Conclusions: The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.<\/jats:p>","DOI":"10.3233\/jad-231335","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T11:26:17Z","timestamp":1717759577000},"page":"193-205","source":"Crossref","is-referenced-by-count":4,"title":["Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals"],"prefix":"10.1177","volume":"100","author":[{"given":"Lena","family":"Sannemann","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DELCODE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bartels","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Brosseron","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Munich, Germany"},{"name":"Institute for Stroke and Dementia Research \u2013 ISD, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fliessbach","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurodegenerative Disease and Geriatric Psychiatry\/Psychiatry, University of Bonn Medical Center, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silka Dawn","family":"Freiesleben","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Berlin, Germany"},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin-Department of Psychiatry and Neurosciences, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Frommann","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurodegenerative Disease and Geriatric Psychiatry\/Psychiatry, University of Bonn Medical Center, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel","family":"Glanz","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Heneka","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine \u2013 LCSB, University of Luxembourg, Belvaux, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Janowitz","sequence":"additional","affiliation":[{"name":"Institute for Stroke and Dementia Research \u2013 ISD, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kilimann","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Rostock, Germany"},{"name":"Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Kleineidam","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurodegenerative Disease and Geriatric Psychiatry\/Psychiatry, University of Bonn Medical Center, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Lammerding","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin-Department of Psychiatry and Neurosciences, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Laske","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, T\u00fcbingen, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Section for Dementia Research, Hertie Institute for Clinical Brain Research, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias H.J.","family":"Munk","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, T\u00fcbingen, Germany"},{"name":"Department of Psychiatry and Psychotherapy, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Munich, Germany"},{"name":"Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany"},{"name":"Munich Cluster for Systems Neurology \u2013 SyNergy, Munich, Munich, Germany"},{"name":"Ageing Epidemiology Research Unit \u2013 AGE, School of Public Health, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Berlin, Germany"},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin-Department of Psychiatry and Neurosciences, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Berlin, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Charit\u00e9, Charit\u00e9platz 1, Berlin, Germany"},{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany"},{"name":"University of Edinburgh and UK DRI, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany"},{"name":"Sheffield Institute for Translational Neuroscience \u2013 SITraN, University of Sheffield, Sheffield, UK"},{"name":"Department of Neuroradiology, University Hospital LMU, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Rostamzadeh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Roy-Kluth","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Katrin","family":"Schild","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Schneider","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurodegenerative Disease and Geriatric Psychiatry\/Psychiatry, University of Bonn Medical Center, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa-Sophie","family":"Schneider","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin-Department of Psychiatry and Neurosciences, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Spottke","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike Jakob","family":"Spruth","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Berlin, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Charit\u00e9, Charit\u00e9platz 1, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Teipel","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Rostock, Germany"},{"name":"Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurodegenerative Disease and Geriatric Psychiatry\/Psychiatry, University of Bonn Medical Center, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, G\u00f6ttingen, Germany"},{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, G\u00f6ttingen, Germany"},{"name":"Department of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine \u2013 iBiMED, University of Aveiro, Aveiro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Wolfsgruber","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Department of Neurodegenerative Disease and Geriatric Psychiatry\/Psychiatry, University of Bonn Medical Center, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"Duezel","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Magdeburg, Germany"},{"name":"Institute of Cognitive Neurology and Dementia Research \u2013 IKND, Otto-von-Guericke University, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany"},{"name":"German Center for Neurodegenerative Diseases \u2013 DZNE, Bonn, Germany"},{"name":"Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases \u2013 CECAD, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-231335_ref1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-180229","article-title":"Using neuropsychological process scores to identify subtle cognitive decline and predict progression to mild cognitive impairment","volume":"64","author":"Thomas","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref4","doi-asserted-by":"crossref","first-page":"E397","DOI":"10.1212\/WNL.0000000000008838","article-title":"Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration","volume":"94","author":"Thomas","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jalz.2009.10.002","article-title":"Outcome over seven years of healthy adults with and without subjective cognitive impairment","volume":"6","author":"Reisberg","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jalz.2018.10.003","article-title":"Subjective cognitive decline and rates of incident Alzheimer\u2019s disease and non\u2013 Alzheimer\u2019s disease dementia","volume":"15","author":"Slot","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/archgenpsychiatry.2010.30","article-title":"Prediction of dementia by subjective memory impairment effects of severity and temporal association with cognitive impairment","volume":"67","author":"Jessen","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.3233\/JAD-231335_ref8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-201184","article-title":"Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline","volume":"80","author":"Ismail","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref9","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1212\/WNL.0000000000005863","article-title":"Subjective cognitive decline and risk of MCI: The Mayo Clinic Study of Aging","volume":"91","author":"van Harten","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11065-021-09522-3","article-title":"Subjective cognitive decline: Level of risk for future dementia and mild cognitive impairment, a meta-analysis of longitudinal studies","volume":"32","author":"Pike","year":"2022","journal-title":"Neuropsychol Rev"},{"key":"10.3233\/JAD-231335_ref11","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.neuropsychologia.2012.08.011","article-title":"Subjective cognitive complaints and amyloid burden in cognitively normal older individuals","volume":"50","author":"Amariglio","year":"2012","journal-title":"Neuropsychologia"},{"key":"10.3233\/JAD-231335_ref12","doi-asserted-by":"crossref","first-page":"675583","DOI":"10.3389\/fnagi.2021.675583","article-title":"Severity of subjective cognitive complaints and worries in older adults are associated with cerebral amyloid-\u03b2 load","volume":"13","author":"Schwarz","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-231335_ref13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13195-019-0515-y","article-title":"Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study","volume":"11","author":"Miebach","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-231335_ref14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","article-title":"The characterisation of subjective cognitive decline","volume":"19","author":"Jessen","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-231335_ref15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3233\/JAD-160407","article-title":"Differential risk of incident Alzheimer\u2019s disease dementia in stable versus unstable patterns of subjective cognitive decline","volume":"54","author":"Wolfsgruber","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archpsyc.63.3.273","article-title":"Depressive symptoms, vascular disease, and mild cognitive impairment: Findings from the cardiovascular health study","volume":"63","author":"Barnes","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.3233\/JAD-231335_ref17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1176\/appi.ajp.2014.13060821","article-title":"Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study","volume":"171","author":"Geda","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-231335_ref18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000357775","article-title":"The Alzheimer\u2019s disease cooperative study prevention instrument project: Longitudinal outcome of behavioral measures as predictors of cognitive decline","volume":"4","author":"Banks","year":"2014","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.3233\/JAD-231335_ref19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.0000000000001238","article-title":"Noncognitive symptoms of early Alzheimer disease: A longitudinal analysis","volume":"84","author":"Masters","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/JAD-170632","article-title":"Risk of conversion to dementia in a mild behavioral impairment group compared to a psychiatric group and to a mild cognitive impairment group","volume":"62","author":"Taragano","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jalz.2015.05.017","article-title":"Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment","volume":"12","author":"Ismail","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-017-0314-2","article-title":"Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer\u2019s disease (DELCODE)","volume":"10","author":"Jessen","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-231335_ref23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/alz.12674","article-title":"Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers","volume":"19","author":"Jessen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-231335_ref25","doi-asserted-by":"crossref","first-page":"S13-21","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer\u2019s disease assessment scale that broaden its scope","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-231335_ref26","first-page":"266","article-title":"The Free and Cued Selective Reminding Test: Evidence of psychometric adequacy","volume":"51","author":"Grober","year":"2009","journal-title":"Psychol Sci Q"},{"key":"10.3233\/JAD-231335_ref27","unstructured":"Petermann F, Lepach AC (2012) Wechsler memory scale. Dtsch \u00dcbersetzung und Adapt der WMS-IV von Davis Wechsler Frankfurt a M Pearson Assess Inf GmbH."},{"key":"10.3233\/JAD-231335_ref28","volume-title":"Neuropsychological assessment","author":"Lezak","year":"2004"},{"key":"10.3233\/JAD-231335_ref29","volume-title":"Symbol digit modalities test (SDMT) Manual (Revised)","author":"Smith","year":"1973"},{"key":"10.3233\/JAD-231335_ref30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"10.3233\/JAD-231335_ref31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0278-2626(92)90112-Y","article-title":"Quantitative and qualitative analyses of clock drawings in Alzheimer\u2019s and Huntington\u2019s disease","volume":"18","author":"Rouleau","year":"1992","journal-title":"Brain Cogn"},{"key":"10.3233\/JAD-231335_ref32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0197-4580(00)82810-9","article-title":"The cerad neuropsychological assessment battery (Cerad-NAB)\u2014 A minimal data set as a common tool for German-speaking Europe","volume":"21","author":"Thalmann","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-231335_ref33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3233\/JAD-160637","article-title":"Face-name associative recognition deficits in subjective cognitive decline and mild cognitive impairment","volume":"56","author":"Polcher","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref34","doi-asserted-by":"crossref","first-page":"e54035","DOI":"10.1371\/journal.pone.0054035","article-title":"Functional neural correlates of attentional deficits in amnestic mild cognitive impairment","volume":"8","author":"van Dam","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-231335_ref35","doi-asserted-by":"crossref","first-page":"e1134","DOI":"10.1212\/WNL.0000000000010142","article-title":"Minor neuropsychological deficits in patients with subjective cognitive decline","volume":"95","author":"Wolfsgruber","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JAD-231335_ref37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.datak.2007.01.002","article-title":"Investigating diversity of clustering methods: An empirical comparison","volume":"63","author":"Gelbard","year":"2007","journal-title":"Data Knowl Eng"},{"key":"10.3233\/JAD-231335_ref38","unstructured":"Sarstedt M , Mooi E (2014) A Concise Guide to Market Research Springer Berlin Heidelberg, Heidelberg, Berlin, Heidelberg."},{"key":"10.3233\/JAD-231335_ref39","first-page":"19","article-title":"The need to report effect size estimates revisited. An overview of some recommended measures of effect size","volume":"1","author":"Tomczak","year":"2014","journal-title":"Trends Sport Sci"},{"key":"10.3233\/JAD-231335_ref40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000095427","article-title":"Subtype of mild cognitive impairment and progression to dementia and death","volume":"22","author":"Yaffe","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-231335_ref41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-231335_ref42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neurobiolaging.2019.02.020","article-title":"Amyloid PET and cognitive decline in cognitively normal individuals: The SCIENCe project","volume":"79","author":"Timmers","year":"2019","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-231335_ref43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamaneurol.2015.3098","article-title":"Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community","volume":"73","author":"Petersen","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-231335_ref44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jagp.2019.03.023","article-title":"Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: The Cache County Study","volume":"28","author":"Burhanullah","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-231335_ref45","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1212\/01.wnl.0000436942.55281.47","article-title":"Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies","volume":"81","author":"Ferman","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1017\/S1041610211002870","article-title":"The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer\u2019s dementia and vascular dementia","volume":"24","author":"Jungwirth","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-231335_ref47","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000207844","article-title":"Relevance of minor neuropsychological deficits in patients with subjective cognitive decline","volume":"101","author":"Stark","year":"2023","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref48","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/geronb\/gbw207","article-title":"Subjective cognitive decline correlates with depression symptoms and not with concurrent objective cognition in a clinic-based sample of older adults","volume":"73","author":"Zlatar","year":"2018","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"10.3233\/JAD-231335_ref49","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1093\/geront\/gnw091","article-title":"Subjective cognitive impairment and affective symptoms: A systematic review","volume":"56","author":"Hill","year":"2016","journal-title":"Gerontologist"},{"key":"10.3233\/JAD-231335_ref50","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1017\/S1041610213000665","article-title":"Factors affecting subjective memory complaints in the AIBL aging study: Biomarkers, memory, affect, and age","volume":"25","author":"Buckley","year":"2013","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-231335_ref51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3233\/JAD-2011-102133","article-title":"Prediction of preclinical Alzheimer\u2019s disease: Longitudinal rates of change in cognition","volume":"25","author":"Riley","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref52","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1212\/WNL.0000000000000650","article-title":"Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology","volume":"83","author":"Monsell","year":"2014","journal-title":"Neurology"},{"key":"10.3233\/JAD-231335_ref53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/brain\/awh451","article-title":"The 9 year cognitive decline before dementia of the Alzheimer type: A prospective population-based study","volume":"128","author":"Amieva","year":"2005","journal-title":"Brain"},{"key":"10.3233\/JAD-231335_ref54","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jalz.2019.09.074","article-title":"Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD","volume":"16","author":"Papp","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3233\/JAD-210251","article-title":"A comparison of cross-sectional and longitudinal methods of defining objective subtle cognitive decline in preclinical Alzheimer\u2019s disease based on cogstate one card learning accuracy performance","volume":"83","author":"Pudumjee","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref56","doi-asserted-by":"crossref","first-page":"e12325","DOI":"10.1002\/dad2.12325","article-title":"Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer\u2019s disease","volume":"14","author":"Alden","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-231335_ref57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-150128","article-title":"Subtle cognitive decline and biomarker staging in preclinical Alzheimer\u2019s disease","volume":"47","author":"Edmonds","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JAD-200087","article-title":"Diagnostic and prognostic accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in preclinical Alzheimer\u2019s disease and incident mild cognitive impairment: Implications for defining subtle objective cognitive impairment","volume":"76","author":"Stricker","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231335_ref59","first-page":"503","article-title":"Base rates of \u201cimpaired\u201d neuropsychological test performance among healthy older adults","volume":"13","author":"Palmer","year":"1998","journal-title":"Arch Clin Neuropsychol"},{"key":"10.3233\/JAD-231335_ref60","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/alz.12163","article-title":"Prediction of dementia of Alzheimer type by different types of subjective cognitive decline","volume":"16","author":"Jessen","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231335_ref61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/psyg.12697","article-title":"Empirically defining the preclinical stages of the Alzheimer\u2019s continuum in the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"21","author":"Kiselica","year":"2021","journal-title":"Psychogeriatrics"},{"key":"10.3233\/JAD-231335_ref62","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ana.26071","article-title":"NIA-AA Alzheimer\u2019s Disease Framework: Clinical characterization of stages","volume":"89","author":"Petersen","year":"2021","journal-title":"Ann Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-231335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:58:24Z","timestamp":1777370304000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-231335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":62,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-231335","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3213352\/v1","asserted-by":"object"}]},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}